Purpose This study aimed to determine the prevalence and molecular characterization of
bedaquiline (BDQ) resistance among rifampicin-resistant tuberculosis (RR-TB) isolates …

There are limited data on combining delamanid and bedaquiline in drug-resistant
tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV …

MDR-TB is a lethal form of TB caused by Mycobacterium tuberculosis strains, which are
resistant to rifampicin and isoniazid. It should be suspected in patients living in high MDRTB …

Background Evaluating treatment outcomes of a cohort of patients is an effective way for
analyzing the effectiveness of a program. Information regarding drug resistance pattern …

The burden of isoniazid-resistant tuberculosis (Hr-TB) and multidrug-and/or rifampicin
monoresistant tuberculosis (MDR/RR-TB) is increasing worldwide, and the high TB burden …

Objectives Multidrug-resistant tuberculosis (MDR-TB) is a major challenge to global health
security. Early identification of MDR-TB patients increases the likelihood of treatment …

Background As new drugs are developed for multidrug-resistant tuberculosis (MDR-TB), the
role of currently used drugs must be reevaluated. Methods We combined individual-level …

Objectives Limited data exist on clinical associations and genotypic correlates of linezolid
resistance in Mycobacterium tuberculosis. We aimed to describe mutations and clinical …

Drug-resistant tuberculosis: advances in diagnosis and manag... : Current Opinion in
Pulmonary Medicine Drug-resistant tuberculosis: advances in diagnosis and management …

A new drug Bedaquiline, a diarylquinoline agent has been approved by the Food and Drug
Administration for the treatment of pulmonary multidrug-resistant tuberculosis. It has been …